Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HAE 
Haemonetics Corporation (HAE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: HAE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $83
1 Year Target Price $83
| 3 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.17% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.46B USD | Price to earnings Ratio 21.61 | 1Y Target Price 83 |
Price to earnings Ratio 21.61 | 1Y Target Price 83 | ||
Volume (30-day avg) 10 | Beta 0.36 | 52 Weeks Range 47.32 - 89.73 | Updated Date 11/14/2025 |
52 Weeks Range 47.32 - 89.73 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 1.11 | Actual 1.27 |
Profitability
Profit Margin 12.67% | Operating Margin (TTM) 21.02% |
Management Effectiveness
Return on Assets (TTM) 6.36% | Return on Equity (TTM) 19.47% |
Valuation
Trailing PE 21.61 | Forward PE 15.6 | Enterprise Value 4388004857 | Price to Sales(TTM) 2.61 |
Enterprise Value 4388004857 | Price to Sales(TTM) 2.61 | ||
Enterprise Value to Revenue 3.3 | Enterprise Value to EBITDA 12.29 | Shares Outstanding 46809672 | Shares Floating 46229700 |
Shares Outstanding 46809672 | Shares Floating 46229700 | ||
Percent Insiders 1.18 | Percent Institutions 110.83 |
Upturn AI SWOT
Haemonetics Corporation
Company Overview
History and Background
Haemonetics Corporation was founded in 1971. It has grown to become a global provider of blood and plasma supplies and software solutions to customers around the world. Key milestones include expansion into new markets and the development of innovative blood management technologies.
Core Business Areas
- Plasma: Provides technology and products for plasma collection, including automated plasma collection systems and software.
- Blood Center: Offers products and solutions for blood donation and component processing, helping blood centers optimize their operations.
- Hospital: Provides blood management solutions for hospitals, focusing on reducing blood transfusion needs and improving patient outcomes.
Leadership and Structure
Haemonetics Corporation is led by a CEO and executive management team. The organizational structure includes functional departments such as R&D, marketing, sales, and operations, with a global presence.
Top Products and Market Share
Key Offerings
- PCS Plasma Collection System: Automated plasma collection technology. A major player in automated plasma collection, competing with Terumo BCT, Grifols. Market share is estimated to be roughly 50% in the automated plasma collection segment for donor centers. Revenue tied to PCS sales and disposable usage is significant. Primary competitors are Terumo BCT and Grifols.
- Cell Saver Elite+ Autotransfusion System: Autotransfusion system that recovers a patient's own blood during surgery. Competitors include LivaNova and Medtronic. Used in hospitals for surgeries with high blood loss.
- TEG Hemostasis Analyzer: Point-of-care diagnostic system for assessing a patient's coagulation status. Competitors include Werfen and Instrumentation Laboratory. Provides rapid insights to guide transfusions.
Market Dynamics
Industry Overview
The blood and plasma technology market is driven by increasing demand for plasma-derived therapies, aging populations, and growing surgical volumes. Regulatory requirements and technological advancements also play a significant role.
Positioning
Haemonetics is a leading provider of blood and plasma technologies, positioned strongly in plasma collection and hospital blood management. The company benefits from a broad product portfolio and a global presence.
Total Addressable Market (TAM)
The global blood and plasma technology market is estimated at approximately $15-20 billion. Haemonetics Corporation holds a solid, but not dominant share of this TAM, with growth opportunities in expanding markets and new products.
Upturn SWOT Analysis
Strengths
- Strong market position in plasma collection
- Broad product portfolio
- Global presence
- Established customer relationships
- Innovative technology
Weaknesses
- Dependence on plasma collection market
- Exposure to regulatory changes
- Competition from larger players
- Potential for product obsolescence
Opportunities
- Expanding into emerging markets
- Developing new blood management technologies
- Acquiring complementary businesses
- Increasing adoption of autotransfusion systems
- Expanding software solutions for blood management
Threats
- Pricing pressure from competitors
- Changes in reimbursement policies
- Product liability claims
- Economic downturns
- Emergence of alternative therapies
Competitors and Market Share
Key Competitors
- TER
- GRIF
- BSX
- ILMN
Competitive Landscape
Haemonetics faces competition from larger medical device companies and specialized blood technology providers. Its strengths lie in its established position in plasma collection and hospital blood management solutions, but it must continue to innovate to maintain its competitive edge.
Major Acquisitions
Cardiva Medical
- Year: 2021
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expanded Haemonetics' portfolio of hospital products with vascular closure systems.
Growth Trajectory and Initiatives
Historical Growth: Discuss Haemonetics Corporation's growth trends over the past years.
Future Projections: Provide projections for Haemonetics Corporation's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Haemonetics Corporation.
Summary
Haemonetics is a solid company with a strong position in the plasma collection market. It benefits from its established customer relationships and innovative technologies. However, the company faces competition and regulatory pressures, and needs to diversify its revenue streams and expand into new markets to sustain long-term growth. Haemonetics needs to innovate and make acquisitions in order to grow and remain relevant in this changing market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Haemonetics Corporation Investor Relations
- Analyst Reports
- Industry Publications
- Company 10K reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change, and readers should conduct their own research before making any investment decisions. Financial information is based on publically available information; current financial metrics for the current year are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haemonetics Corporation
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 1991-05-09 | CEO, President & Director Mr. Christopher A. Simon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3023 | Website https://www.haemonetics.com |
Full time employees 3023 | Website https://www.haemonetics.com | ||
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.